🎯 What drives Path for Young? Our program is built around 7 core objectives, each one shaping how we support young patients facing breast cancer, today and tomorrow: 1️⃣ Reducing chemotherapy without compromising outcomes 2️⃣ Empowering care with personalized digital health tools 3️⃣ Understanding patient needs and societal impact 4️⃣ Guiding policy with genomic testing and digital tools 5️⃣ Putting patients at the heart of cancer research 6️⃣ Building a secure and open digital platform for patients 7️⃣ Sharing knowledge and advancing global breast cancer care Each of our partner centers contributes its expertise to bring these objectives to life, from clinical research to digital innovation to patient advocacy. Together, we're working toward smarter, kinder, more personalized cancer care. 💙 #PathForYoung #BreastCancer #DigitalHealth #PatientCentered #CancerResearch

🤝Patient co-creation and representation is at the heart of Path For Young. From conception to the dissemination of results, the project works to involve patients at every stage - understanding their experience in a chemotherapy de-escalation trial, improving recruitment and implementation, and making sure their needs are truly integrated. A dedicated working group, combining clinical, academic, industrial, and nonprofit expertise, ensures patients' voices are heard throughout. 👉More about patient engagement: path-for-young.unicancer.fr/… #PathForYoung #PatientEngagement #ClinicalTrial

🔬 Who is Who? - Meet the people behind Path For Young! 👩‍⚕️ Dr. Maria Alice Franzoi (@AliceFranzoi), medical oncologist and researcher, leads Work Package 4 of the Path For Young project. At the Cancer Survivorship Group at Gustave Roussy, she drives work on care pathways, digital health, including the co-design of patient-centred resources to facilitate care delivery. Her goal: making OPTIMA Young a clinical trial truly built withand for patients. 🎗️ A toolkit of resources co-created with patients and healthcare providers will serve the clinical trial, aiming to tackle pre-identified implementation barriers, enable equitable participation, improve shared decision making and patient experience during the trial. #PathForYoung #ClinicalTrial #BreastCancer #PatientCentered

🤝Great to gather the #OPTIMAYOUNG team at the UCBG/FEMNET Scientific Day in Paris! The scientific and sponsor teams are working hand in hand, fully mobilised to support the first French centres now open for inclusion. With around fifteen centres already recruiting across France, momentum is building! 💙 Thank you again Kenza Cheurfa, Aure Vanhecke, Fanny Ledu, Ines Vaz-Luis, Victorina Mananga, Maria Alice Franzoi and Mack Doël Gbaguidi #FEMNET #UCBG #BreastCancer #ClinicalResearch #PathForYoung #WomensHealth

📷 A landmark moment for the #OPTIMAYOUNG trial: our first patient has been enrolled on June 26th at Clinique Pasteur in Brest, France! 📷 This is the result of months of hard work, dedication, and collaboration across the entire consortium. A huge thank you to the team at Clinique Pasteur and to all the recruiting centres working alongside us! This milestone officially opens the inclusion period, which is expected to run until August 2028. Together, we are moving one step closer to answering a crucial question for premenopausal breast cancer patients: can we safely de-escalate chemotherapy without compromising outcomes? 📷 #BreastCancer #ClinicalTrial #PathForYoung #Oncology #WomensHealth #PatientFirst

New results from #ASCO2026 OPTIMA reinforces the clinical value of Prosigna and the ≤60 threshold to identify patients unlikely to derive meaningful additional benefit from chemotherapy. Although encouraging, the premenopausal sample size in OPTIMA alone is not sufficient to provide a definitive answer: definitive confidence for premenopausal patients will require OPTIMA + premenopausal extension + OPTIMA-YOUNG data. Congratulations to the OPTIMA team on this great achievement. We are grateful to continue this effort with you, and with all partners and investigators associated with our consortium. #PathForYoung #OptimaYoung

Stay tuned for #ASCO2026! OPTIMA trial results — including first insights in premenopausal population — will be presented. These data will contribute to the PATH-FOR-YOUNG / OPTIMA-YOUNG joint analysis on genomic assay–guided chemotherapy de-escalation. #PathForYoung #OptimaYoung

Great news! 🎉 OPTIMA-Young is moving fast towards opening its first centers in France 🇫🇷 The first centers are expected to start enrolling patients in the coming months — an important step forward for the project and for young breast cancer patients. #PathForYoung #OptimaYoung

On May 12th, we celebrated #InternationalNursesDay and honor the dedication, compassion, and resilience of nurses worldwide. Thank you for the incredible impact you make every day in patient care, research, and saving lives. 💙 #NursesDay #PathForYoung

Understanding the patient journey is key to ensure research is aligned with patients and clinicians needs and expectations. PATH-FOR-YOUNG researchers engaged with a co-creation board for this purpose. sciencedirect.com/science/ar… #PathForYoung

At Path-for-Young, we’re committed to keeping patients informed, supported, and empowered. 🎥New short videos—co-created with our Patient Committee—answer key questions about trial participation and shared decision-making. Coming soon at: path-for-young.unicancer.fr/ #PathForYoung

On Jan 28th, the Path-for-Young General Assembly brought together investigators from all participating centers to share updates and plan the next steps toward the study launch. We also heard the latest progress from the OPTIMA trial, now nearing completion.

🌷 Happy International Women’s Day! At Path-For-Young, we work to improve care and outcomes for young women with breast cancer through research, collaboration and innovation. Today we celebrate the women in science and the courageous patients who inspire our work. #PathForYoung

Klineo, a Path-for-Young partner, is expanding to Belgium, Italy & Germany. The free platform helps oncologists quickly identify trials, match patients in under a minute, and track referrals—supporting patient engagement and recruitment across Europe. klineo.com

Recruitment for the OPTIMA trial closed on 12 Dec 2025, reaching 98.5% of the 4,500-participant target. Around 1,650–1,660 premenopausal patients will contribute to Optima-young analysis. Thanks to all participants and teams for making this milestone possible. #PathforYoung

Path-for-Young partners with the @UniversityLeeds to strengthen health economics and technology assessment. Dr. Alison Smith will co-lead WP8-9, helping ensure personalised breast cancer care is effective, sustainable, and patient-centred. #PathforYoung

On World Cancer Day, we highlight the importance of personalised, equitable care. Path-for-Young is transforming breast cancer care for young women through research, international collaboration, and digital tools like the RESILIENCE app. Learn more: path-for-young.unicancer.fr/

The Optima-young trial protocol, including the OPTIMIZE digital substudy, has been submitted in Europe. First patients expected Q1 2026, with all sites active by June. This brings us closer to safer, personalised care for young women with HR+/HER2− breast cancer. #PathforYoung

At ESMO 2025, Path-for-Young shared results from a co-creation study within Optima-young. Patient partners and clinicians identified barriers & facilitators in chemo de-escalation trials, shaping the protocol & patient support tools. Read more: annalsofoncology.org/article…